Table 2.
Comparison between the OS and PFS of trials with chemotherapeutic agents in patients with no prior chemotherapy.
| Reference | Treatment | Overall Survival (OS) | Progression-Free Survival (PFS) |
|---|---|---|---|
| Uesaka et al. [11] | 1- Gemcitabine 2- S-1 |
1- 25.5 months 2- 46.5 months |
NA |
| Hammel et al. [12] | 1- Gemcitabine alone 2- Gemcitabine plus erlotinib |
1- 13.6 months 2- 11.9 months |
NA |
| Ueno et al. [15] | Nab-paclitaxel followed by gemcitabine. | 13.5 months | 6.5 months |
| Imaoka et al. [10] | 1- Gemcitabine plus S-1 2- S-1 alone 3- Gemcitabine alone |
1- 10.2 months 2- 8.0 months 3- 8.5 months |
NA |
| Catenacci et al. [16] | 1- Vismodegib plus gemcitabine 2- Gemcitabine plus placebo |
1- 6.9 months 2- 6.1 months |
1- 4.0 months 2- 2.5 months |
| Goji et al. [9] | Fixed-dose-rate gemcitabine and S-1 (both orally). A total radiation dose of 50.4 Gy was delivered concurrently. | 16.0 months | 11.0 months |
| Wang et al. [13] | 1- Gemcitabine 2- Gemcitabine plus erlotinib |
1- 4.4 months 2- 7.2 months |
1- 2.4 months 2- 3.8 months |
| Shimoda et al. [2] | 1- Adjuvant chemotherapy with S-1 after resection of pancreatic cancer 2- Adjuvant chemotherapy with gemcitabine after resection of pancreatic cancer |
1- 21.5 months 2- 18.0 months |
NA |
| Cho et al. [17] | Two cycles of gemcitabine and docetaxel followed by 5FU-based chemoradiation. Four weeks after completing chemoradiation, two cycles of gemcitabine and docetaxel were administered. | 17.0 months for patients with pancreatic cancer and 23.0 months for patients with resected biliary tract cancer. | NA |
| Goldstein et al. [14] | 1- Nab-paclitaxel + gemcitabine 2- Gemcitabine alone |
1- 8.7 months 2- 6.6 months |
NA |
| Petrioli et al. [18] | 1- GEMOXEL arm: combination of single-agent Gemcitabine, Oxaliplatin, and Capecitabine 2- Gemcitabine alone |
1- 11.9 months 2- 7.1 months |
1- 6.8 months 2- 3.7 months |
| Sherman et al. [20] | 1- Neoadjuvant gemcitabine, docetaxel, and capecitabine followed by gemcitabine and capecitabine/radiation therapy in patients in the arterial arm 2- Neoadjuvant gemcitabine, docetaxel, and capecitabine in patients in the venous arm |
1- 29.0 months 2- More than 42.0 months 32.5 months for all 45 patients. |
NA |
| Lombard-Bohas et al. [34] | Everolimus or placebo | NA | 11.4 months with everolimus and 5.4 months with placebo. |
| Bergmann et al. [21] | 1- Gemcitabine 2- Gemcitabine plus sunitinib |
1- 8.5 months 2- 7.01 months |
1- 3.1 months 2- 2.7 months |
| Tai et al. [39] | 1- Leucovorin, gemcitabine, cisplatin, and fluorouracil 2- Leucovorin, gemcitabine, cisplatin, and fluorouracil plus bevacizumab and cetuximab. |
1- 7.0 months 2- 10.0 months |
1- 3.0 months 2- 9.0 months |
| Lee et al. [23] | 1- Gemcitabine plus capecitabine 2- Gemcitabine alone |
1- 10.3 months 2- 7.5 months |
1- 6.2 months 2- 5.3 months |
| Satoi et al. [38] | Intravenous and intraperitoneal paclitaxel plus S-1. | 16.3 months | NA |
NA—not available.